| 参考文献: |
1: Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Epub ahead of print. PMID: 36018295.
2: Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer. Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377. Epub ahead of print. Erratum for: Cancer Res. 2022 Jun 14;: PMID: 36006687.
3: Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Epub ahead of print. Retraction in: Cancer Res. 2022 Aug 26;:OF1. Erratum in: Cancer Res. 2022 Aug 25;:OF1. PMID: 35700239. |